MRNA Jan 2024 140.000 call
| Previous close | 2.0000 |
| Open | 2.0000 |
| Bid | 2.0400 |
| Ask | 2.1300 |
| Strike | 140.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.7300 - 2.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.45k |
Yahoo FinanceNovavax expects COVID-19 boosters to be available next week
Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.
Yahoo FinanceBehind the new malaria vaccine endorsed by the World Health Organization
The Serum Institute of India has received a recommendation from WHO for malaria doses using a Novavax adjuvant.
- Financial Times
Moderna reports trial success for dual Covid and flu vaccine
Moderna’s combined Covid and influenza vaccine was as effective as separate shots in an early stage trial, giving the US biotech company hope that the more convenient way of protecting against the diseases could be approved by 2025. Interim data measuring antibody levels from the phase-1/2 trial showed the combined jab elicited a similar or greater immune response to flu viruses as currently approved flu vaccines, including Sanofi’s high-dose shots designed for the elderly. The jab also elicited a similar immune response to Sars-Cov-2 as Moderna’s Covid-19 booster, known as Spikevax.
